IP Library Patent Application 17228146
Patent Application
App. No. 17/228,146

COMPOSITIONS AND METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/228,146
Abstract

Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.

Claims (28)

1 - 43 . (canceled)

44 . A method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, comprising administering to the mammalian subject in need thereof a composition comprising

a bacterial population consisting of from seven to nine isolated bacterial strains, wherein two of the bacterial strains are Clostridium innocuum and Blautia producta; and

a capsule substantially encapsulating the bacterial population.

45 . The method of claim 44 , wherein the gastrointestinal disease, disorder or condition is relapsing diarrhea caused by Clostridium difficile, ulcerative colitis, colitis, Crohn's disease, or irritable bowel disease.

46 . The method of claim 44 , wherein the gastrointestinal disease, disorder or condition is recurrent Clostridium difficile infection.

47 . The method of claim 44 , wherein the gastrointestinal disease, disorder or condition is Clostridium difficile infection.

48 . The method of claim 44 , wherein the composition is administered once a day for several days or more than once a day on the day of administration.

49 . The method of claim 44 , wherein the composition is administered once prior to improvement of the disease, disorder or condition.

50 . The method of claim 44 , wherein the composition is administered at intervals greater than two days.

51 . The method of claim 44 , wherein the mammalian subject has not received at least two doses of a vancomycin, a metronidazole, or an antibiotic compound within one week prior to administration of the composition.

52 . The method of claim 44 , wherein the mammalian subject is not suffering from relapsing diarrhea caused by C. difficile.

53 . The method of claim 44 , wherein the mammalian subject has received an antibiotic prior to administration of the composition.

54 . The method of claim 53 , wherein the antibiotic is an aminoglycoside antibiotic, amoxicillin, ampicillin, Augmentin, a cephalosporin, clavulanate potassium, clindamycin, colistin gentamycin, kanamycin, metronidazole, vancomycin, or a combination thereof.

55 . The method of claim 44 , wherein the mammalian subject has not previously received an antibiotic compound in the one month prior to administration of the composition.

56 . The method of claim 44 , wherein the composition is formulated for oral or gastric administration.

57 . The method of claim 44 , wherein the bacterial strains are present at a concentration of at least 1×10 4 viable bacteria.

58 . The method of claim 44 , wherein at least one of the bacterial strains is provided in a concentration of greater than 1×10 9 viable bacteria.

59 . The method of claim 44 , wherein the bacterial population consists of seven bacterial strains.

60 . The method of claim 44 , wherein the bacterial population consists of eight bacterial strains.

61 . The method of claim 44 , wherein the bacterial population consists of nine bacterial strains.

62 . The method of claim 44 , wherein the composition further comprises an excipient.

63 . The method of claim 44 , wherein the bacterial strains are lyophilized.

64 . The method of claim 44 , wherein the bacterial strains are in vegetative form.

65 . The method of claim 44 , wherein the bacterial strains are in spore form.

66 . A method of treating recurrent Clostridium difficile infection in a subject in need thereof, comprising administering to the subject a composition comprising

a bacterial population consisting of from seven to nine isolated bacterial strains, wherein two of the bacterial strains are Clostridium innocuum and Blautia producta; and

a capsule substantially encapsulating the bacterial population.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2024
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: SERES THERAPEUTICS, INC.
Reel/Frame 069082/0849 →
SECURITY INTEREST Recorded Apr 27, 2023
From: SERES THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 063485/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2021
From: AFEYAN, NOUBAR B.; MCKENZIE, MARY-JANE LOMBARDO; LITCOFSKY, KEVIN DANIEL; COOK, DAVID N.; GOODMAN, BRIAN
To: SERES HEALTH, INC.
Reel/Frame 058393/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2021
From: HENN, MATTHEW R.; VON MALTZAHN, GEOFFREY
To: SERES THERAPEUTICS, INC.
Reel/Frame 058393/0621 →
CHANGE OF NAME Recorded Dec 15, 2021
From: SERES HEALTH, INC.
To: SERES THERAPEUTICS, INC.
Reel/Frame 058518/0024 →